RESUMEN
OBJECTIVE: A simple intervention is needed that could protect the heart against infarction during limited-access coronary artery bypass grafting. Adenosine and norepinephrine can precondition the heart with resulting protection, but adverse hemodynamic effects prevent clinical application. Because heart rate, blood pressure, and contractility effects of these two drugs are diametrically opposite, a mixture might be beneficial. METHODS: A superficial branch of the left coronary artery of rabbits was surrounded with a suture. Infarction was produced in all hearts by a 30-minute coronary artery occlusion. Infarct size after reperfusion was measured and is presented as a percentage of the risk zone. The effect of 5-minute intravenous co-infusion of adenosine (20 mg/kg) and norepinephrine (0.1 mg/kg) 15 minutes before ischemia was examined. In addition, the protective effect of three sequential intravenous bolus injections of adenosine at either 0.2 or 0.4 mg/kg was evaluated. RESULTS: Thirty minutes of regional ischemia caused infarction of 40% +/- 4% of the risk zone. The combination of adenosine and norepinephrine caused no change in blood pressure but rather protected the heart, with infarction of only 9% +/- 2% of the risk zone (p = 0.0001 vs control). Adenosine-norepinephrine co-infusion still protected the heart when the interval between infusion and ischemia was extended to 60 minutes, but it did not protect with a 120-minute interval. Intravenous bolus injections of adenosine resulted in cardiac slowing and marked hypotension. Boluses of 0.2 mg/kg resulted in a minimal, but significant, reduction in infarct size, whereas the higher dose provided no protection. CONCLUSION: Adenosine-norepinephrine co-infusion provides a feasible and safe parenteral method for preconditioning the heart.
Asunto(s)
Adenosina/administración & dosificación , Agonistas alfa-Adrenérgicos/administración & dosificación , Fármacos Cardiovasculares/administración & dosificación , Corazón/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Precondicionamiento Isquémico Miocárdico/métodos , Norepinefrina/administración & dosificación , Animales , Presión Sanguínea/efectos de los fármacos , Estudios de Factibilidad , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Infusiones Intravenosas , Masculino , Infarto del Miocardio/patología , ConejosAsunto(s)
Prolactina/farmacología , Urodelos , Animales , Hipofisectomía , Pierna/crecimiento & desarrollo , Regeneración/efectos de los fármacos , Piel/efectos de los fármacos , Tiroxina/farmacología , Urodelos/efectos de los fármacos , Urodelos/crecimiento & desarrollo , Urodelos/fisiología , Equilibrio HidroelectrolíticoAsunto(s)
Músculos/inervación , Ambystoma , Animales , Larva , Microscopía Electrónica , Desarrollo de Músculos , Músculos/ultraestructuraRESUMEN
Ischemic preconditioning protects the rabbit myocardium from infarction from a subsequent ischemia, and adenosine receptors appear to be involved in this protection. The present study attempts to determine when adenosine receptors must be occupied to achieve protection by infusing the adenosine receptor antagonist PD-115,199 at various time points during the study. Open-chest rabbits were subjected to 30 min of regional ischemia followed by 3 h of reperfusion and had 38 +/- 4% infarction of the risk zone. When hearts were preconditioned by 5 min of ischemia and 10 min reperfusion before the 30-min period of ischemia, only 9 +/- 2% infarction occurred. PD-115,199 given 5 min before the ischemic preconditioning episode blocked the protective effect of preconditioning (39 +/- 5% infarction). PD-115,199 also blocked the protection when given between the ischemic preconditioning episode and the 30-min period of ischemia (30 +/- 4% infarction). PD-115,199 given at the end of 30 min of ischemia did not block protection in preconditioned (PC) hearts (17 +/- 5% infarction) and had no effect on non-PC hearts (44 +/- 6% infarction). In prior studies we found that exogenous adenosine could substitute for ischemia to precondition the heart, indicating that adenosine is an initiator of preconditioning. These results, however, indicate that adenosine receptors must also be occupied during the long ischemic period for preconditioning to be protective and suggest that adenosine is a mediator of preconditioning as well.
Asunto(s)
Adaptación Fisiológica , Enfermedad Coronaria/fisiopatología , Antagonistas Purinérgicos , Adaptación Fisiológica/efectos de los fármacos , Animales , Femenino , Masculino , Infarto del Miocardio/patología , Purinas/farmacología , Conejos , Recurrencia , Sulfonamidas/farmacología , Factores de TiempoRESUMEN
Ischemic preconditioning renders the heart resistant to infarction by an unknown mechanism. This study tests whether preconditioning may be working through activation of ATP-sensitive potassium channels. If that were the case, then blockade of the channels should eliminate preconditioning's protection, and activation of these channels should mimic it. Thirty minutes of regional coronary ischemia followed by 3 hours of reperfusion caused 38.0 +/- 3.7% of the risk zone to become infarcted in control rabbits. Preconditioning with 5-minute ischemia followed by a 10-minute reperfusion before the 30-minute insult caused only 8.8 +/- 2.1% infarction, which was a reduction of 29.2% in infarct size by preconditioning (p < 0.01 versus control value). Pretreatment with the potassium channel blocker glibenclamide at three different concentrations significantly elevated infarct size in the nonpreconditioned hearts at all doses. Preconditioning, however, continued to limit infarct size by an amount not different from that seen in the control group at all doses of glibenclamide. Pinacidil, a potassium channel agonist, given before a 30-minute ischemic insult resulted in infarct sizes no different from that seen in nonpreconditioned control rabbits. We conclude that ATP-sensitive potassium channels are not involved in preconditioning in the rabbit heart; however, blocking those channels does exacerbate ischemia.